Autologous cardiac micrografts as support therapy to coronary artery bypass surgery
| Autor: | Antti Vento, Harri Sintonen, Tatu Juvonen, Juhani A Stewart, Tommi Pätilä, Ari Harjula, Annu Nummi, Raili Suojaranta, Markku Kupari, Kari Teittinen, Milla Lampinen, Esko Kankuri, Tuomo Nieminen, Severi Mulari, Sari Kivistö |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Ejection fraction business.industry Ischemia Hemodynamics 030204 cardiovascular system & hematology medicine.disease 3. Good health Cardiac surgery Transplantation 03 medical and health sciences Coronary artery bypass surgery 0302 clinical medicine Internal medicine Adjuvant therapy Cardiology Medicine cardiovascular diseases 030212 general & internal medicine business |
| DOI: | 10.1101/2021.03.05.21252995 |
| Popis: | ObjectivesCardio-regenerative cell therapies offer additional biologic support to coronary artery bypass surgery (CABG) for treating the myocardium suffering from or damaged by ischemia. This phase 1, open-label study assessed the safety and feasibility of epicardial transplantation of atrial appendage micrografts (AAMs) in patients undergoing CABG surgery.MethodsTwelve consecutive patients destined for CABG surgery were included in the study. Six patients received AAMs during their operation and six patients were CABG-operated without AAMs treatment. Data from 30 elective CABG patients was collected for a conjunctive control group. The AAMs were processed during the operation from a biopsy collected from the right atrial appendage. They were delivered epicardially on the infarct scar site identified in preoperative CMR. The primary outcome measures at six-months follow-up were i) patient safety in terms of hemodynamic and cardiac function over time and ii) feasibility of therapy administration in a clinical setting. Secondary outcome measures were left ventricular wall thickness, change in myocardial scar tissue volume, changes in left ventricular ejection fraction, plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, NYHA class, number of days in hospital and changes in the quality of life.ResultsEpicardial transplantation of AAMs was safe and feasible to be performed in conjunction with CABG surgery. CMR demonstrated an increase in viable cardiac tissue at the infarct site in patients receiving AAMs treatment.ConclusionTransplantation of AAMs shows good clinical applicability as adjuvant therapy to cardiac surgery and can additionally serve as a delivery platform for cardiac gene therapies.Trial RegistrationClinicalTrials.gov identifier NCT02672163 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|